FTO and acute myeloid leukemia: Moreover, FTO inhibitors such as R-2HG, FB23, FB23–2, CS1 and CS2 can suppress the progression of AML in vitro and in vivo, further indicating that m6A regulators may be promising therapeutic targets for AML.